Carmen Landaverde, MD
Transplant Hepatology · San Antonio, TXNPI 1902093263
Payments from drug & device makers
Across 504 payments — averaging $1502.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$369K
- Ipsen Bioscience Inc.$123K
- Intercept Pharmaceuticals, Inc.$64K
- Madrigal Pharmaceuticals$53K
- Boehringer Ingelheim International GmbH$42K
- Gilead$33K
- plus $73K from 20 others
What the payments were for
- Consulting fees$27,17514%
- Speaking & faculty fees$130,97169%
- Travel & lodging$17,8969%
- Food & beverage$12,6927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $368,966 |
| Ipsen Bioscience Inc. | 52 | $123,353 |
| Intercept Pharmaceuticals, Inc. | 108 | $63,958 |
| Madrigal Pharmaceuticals | 47 | $53,435 |
| Boehringer Ingelheim International GmbH | 31 | $41,534 |
| Gilead | 77 | $32,711 |
| Regeneron | 6 | $20,304 |
| Ipsen Biopharmaceuticals, Inc | 30 | $19,110 |
| Boehringer Ingelheim RCV GmbH & Co KG | 17 | $12,700 |
| Mirum Pharmaceuticals, Inc. | 34 | $11,221 |
| Boston Scientific | 14 | $2,952 |
| Albireo Pharma, Inc. | 3 | $2,509 |
| Eli Lilly | 2 | $1,849 |
| Novo Nordisk | 4 | $1,253 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 42 | $591 |
| AstraZeneca(2 entities) | 5 | $197 |
| Orphalan Inc | 7 | $141 |
| Histosonics, Inc. | 1 | $140 |
| Dova Pharmaceuticals | 3 | $130 |
| Amgen | 1 | $120 |
| Exelixis Inc. | 5 | $74 |
| Mallinckrodt Hospital Products Inc. | 3 | $66 |
| Eton Pharmaceuticals, Inc. | 1 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| AbbVie | 1 | $27 |
| Travere Therapeutics, Inc. | 2 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$61,990
- REZDIFFRA$52,489
- Livdelzi$30,404
- IQIRVO$14,947
- Livmarli$10,313
- Bylvay$2,475
- TheraSphere Y90 Glass Microspheres 10 GBq$2,351
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$384
- Epclusa$348
- GENERAL VASCULAR INTERVENTION$123
- KRYSTEXXA$120
- IMFINZI$103
How this compares
$757,440 in reported general payments places this provider in the 80th percentile of 28 transplant hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 28 | $315,164 |
| XifaxanRifaximin | 45 | $164,269 |
| RezdiffraResmetirom | 14 | $55,351 |
| Ursodiol | 506 | $48,572 |
| Mycophenolic AcidMycophenolate Sodium | 21 | $7,445 |
| Mycophenolate Mofetil | 77 | $6,790 |
| Lactulose | 243 | $5,807 |
| Tacrolimus | 64 | $3,283 |
| ConstuloseLactulose | 165 | $3,053 |
| Spironolactone | 238 | $2,356 |
| Entecavir | 25 | $1,530 |
| CholestyramineCholestyramine (With Sugar) | 16 | $1,501 |
| Acamprosate Calcium | 16 | $1,200 |
| Methylprednisolone | 15 | $1,155 |
| Azathioprine | 35 | $685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $63,958 | $315,16428 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $591 | $164,26945 claims |
| Madrigal PharmaceuticalsRezdiffra | $53,435 | $55,35114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 transplant hepatology providers in Texas.
Other transplant hepatology in San Antonio
- Madhavi RudrarajuSan Antonio$8M
- Kamran SafdarSan Antonio$4K
- Omer JunaidiSan Antonio$1K
- Hakan AkinSan Antonio$235
- Erin SpenglerSan Antonio$76
- Abdullah MubarakTyler$4.2M
- Mangesh PagadalaDallas$1.9M
- David VictorHouston$1.3M
- Prasun JalalHouston$941K
- Fernando MembrenoMcAllen$736K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.